Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers

Jessica A. Waller, Joseph A. Tamm, Aicha Abdourahman, Alan Pehrson, Yan Li, Manuel Cajina, Connie Sánchez

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity. However, the effect of chronic vortioxetine treatment on expression of neuroplasticity and neurodevelopmental biomarkers in naïve rats has not been evaluated. In the present study, we demonstrate that vortioxetine at a range of doses regulates expression of genes associated with plasticity in the frontal cortex, hippocampus, region encompassing the amygdala, as well as in blood, and displays similar effects relative to the SSRI fluoxetine in adult naïve rats. These genes encode immediate early genes (IEGs), translational regulators, and the neurodevelopmental marker Sema4g. Similar findings detected in brain regions and in blood provide a potential translational impact, and vortioxetine appears to consistently regulate signaling in these networks of neuroplasticity and developmental markers.

Original languageEnglish
Pages (from-to)192-203
Number of pages12
JournalEuropean Neuropsychopharmacology
Volume27
Issue number2
DOIs
StatePublished - 1 Feb 2017

Fingerprint

Rodentia
Neuronal Plasticity
Gene Expression
Antidepressive Agents
Serotonin Uptake Inhibitors
Immediate-Early Genes
Fluoxetine
Frontal Lobe
Amygdala
Hippocampus
Up-Regulation
Biomarkers
vortioxetine
Brain
Genes

Keywords

  • Immediate early gene
  • Multimodal
  • Neurodevelopment
  • Neuroplasticity
  • Transcription regulation

Cite this

Waller, Jessica A. ; Tamm, Joseph A. ; Abdourahman, Aicha ; Pehrson, Alan ; Li, Yan ; Cajina, Manuel ; Sánchez, Connie. / Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. In: European Neuropsychopharmacology. 2017 ; Vol. 27, No. 2. pp. 192-203.
@article{f006d169403c48d59d3d89b9d1806d75,
title = "Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers",
abstract = "The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity. However, the effect of chronic vortioxetine treatment on expression of neuroplasticity and neurodevelopmental biomarkers in na{\"i}ve rats has not been evaluated. In the present study, we demonstrate that vortioxetine at a range of doses regulates expression of genes associated with plasticity in the frontal cortex, hippocampus, region encompassing the amygdala, as well as in blood, and displays similar effects relative to the SSRI fluoxetine in adult na{\"i}ve rats. These genes encode immediate early genes (IEGs), translational regulators, and the neurodevelopmental marker Sema4g. Similar findings detected in brain regions and in blood provide a potential translational impact, and vortioxetine appears to consistently regulate signaling in these networks of neuroplasticity and developmental markers.",
keywords = "Immediate early gene, Multimodal, Neurodevelopment, Neuroplasticity, Transcription regulation",
author = "Waller, {Jessica A.} and Tamm, {Joseph A.} and Aicha Abdourahman and Alan Pehrson and Yan Li and Manuel Cajina and Connie S{\'a}nchez",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.euroneuro.2016.11.014",
language = "English",
volume = "27",
pages = "192--203",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "2",

}

Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. / Waller, Jessica A.; Tamm, Joseph A.; Abdourahman, Aicha; Pehrson, Alan; Li, Yan; Cajina, Manuel; Sánchez, Connie.

In: European Neuropsychopharmacology, Vol. 27, No. 2, 01.02.2017, p. 192-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers

AU - Waller, Jessica A.

AU - Tamm, Joseph A.

AU - Abdourahman, Aicha

AU - Pehrson, Alan

AU - Li, Yan

AU - Cajina, Manuel

AU - Sánchez, Connie

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity. However, the effect of chronic vortioxetine treatment on expression of neuroplasticity and neurodevelopmental biomarkers in naïve rats has not been evaluated. In the present study, we demonstrate that vortioxetine at a range of doses regulates expression of genes associated with plasticity in the frontal cortex, hippocampus, region encompassing the amygdala, as well as in blood, and displays similar effects relative to the SSRI fluoxetine in adult naïve rats. These genes encode immediate early genes (IEGs), translational regulators, and the neurodevelopmental marker Sema4g. Similar findings detected in brain regions and in blood provide a potential translational impact, and vortioxetine appears to consistently regulate signaling in these networks of neuroplasticity and developmental markers.

AB - The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity. However, the effect of chronic vortioxetine treatment on expression of neuroplasticity and neurodevelopmental biomarkers in naïve rats has not been evaluated. In the present study, we demonstrate that vortioxetine at a range of doses regulates expression of genes associated with plasticity in the frontal cortex, hippocampus, region encompassing the amygdala, as well as in blood, and displays similar effects relative to the SSRI fluoxetine in adult naïve rats. These genes encode immediate early genes (IEGs), translational regulators, and the neurodevelopmental marker Sema4g. Similar findings detected in brain regions and in blood provide a potential translational impact, and vortioxetine appears to consistently regulate signaling in these networks of neuroplasticity and developmental markers.

KW - Immediate early gene

KW - Multimodal

KW - Neurodevelopment

KW - Neuroplasticity

KW - Transcription regulation

UR - http://www.scopus.com/inward/record.url?scp=85009784259&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2016.11.014

DO - 10.1016/j.euroneuro.2016.11.014

M3 - Article

C2 - 28108062

AN - SCOPUS:85009784259

VL - 27

SP - 192

EP - 203

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 2

ER -